Homepage
Upcoming Webinar: Strategies for Screening and Characterizing Targeted Covalent Inhibitors
Learn about innovative approaches to screen for covalent binders, strategies for the synthesis of covalent warheads, and assays to optimize the DMPK properties of these molecules
Publication: Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library ML
Learn about the the effectiveness of utilizing DEL screening data in conjunction with deep learning models for the discovery of novel drug-like hits beyond the conventional DEL chemical space
WuXi Biology
A full spectrum of biology services and solutions, supporting stand-alone and integrated projects, from target discovery to candidate selection and into the clinic
On-Demand Webinar: Empowering Early Discovery of Peptide Drugs
Learn about recent advancements in peptide drug discovery and strategies that are crucial for developing potent and orally available peptide drugs.
Publication: A µ-Opioid Receptor Modulator that Works Cooperatively with Naloxone
Learn how researchers successfully identified selective negative allosteric modulators for the μ-opioid receptor using DNA-encoded library (DEL) technology
Enabling Unbounded Possibilities
WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic. Our world-class discovery platform is backed by nearly 3000 scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities. From small molecules, oligonucleotides, and peptides to antibodies, cell, and gene therapies, our state-of-the-art services, fast turnaround times, and quick study launches meet the diverse needs of our clients.
Speak with a SpecialistTarget Discovery to Candidate Selection and Beyond
Supporting stand-alone and integrated projects
Comprehensive platform from target ID to drug candidates
Target Identification and Validation
Finding druggable targets
Comprehensive coverage of target classes and therapeutic modalities
Hit Identification
Screening services to accelerate drug discovery
Integrated platform with diverse methods to identify hit compounds
Hit Validation and Early Optimization
Confirming chemistry tractability
In vitro screening platform to support medicinal chemistry
Lead Discovery Services
Enhancing the most promising compounds
In vivo services to accelerate drug discovery
Preclinical Drug Development
Enabling the selection of the best candidates
Integrated platform for preclinical R&D to accelerate timelines
Investigational New Drug Discovery
Comprehensive IND enabling testing platform
Supporting clients from research to market
Latest Science
Latest Article
How Peptide Vaccines are Reshaping Cancer Immunotherapy
Peptide Vaccines are Reshaping Cancer Immunotherapy
VIEW ArticleLatest Publication
Highly Selective Novel Heme Oxygenase-1 Hits Found by...
Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library ML
VIEW PublicationLatest Publication
Recognition of NIS1 by BRI1-Associated Receptor Kinase 1
Recognition of NIS1 by BRI1-Associated Receptor Kinase 1
VIEW PublicationLatest Poster
TLR8 Mouse Model to Evaluate anti-HBV Agents
TLR8 Mouse Model to Evaluate anti-HBV Agents
VIEW PosterLatest Publication
Discovery of Potent, Selective, and Orally Available IRE1...
Discovery of Potent, Selective, and Orally Available IRE1 alpha Inhibitors
VIEW PublicationLatest Publication
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors
Papain-like Protease Inhibitors
VIEW PublicationLatest Publication
Novel DEL Hit That Binds in the Cbl-b...
Novel DEL Hit That Binds in the Cbl-b SH2 Domain
VIEW PublicationLatest Publication
Cardiac Manifestations of Fabry Disease
Cardiac manifestations of Fabry disease
VIEW PublicationLatest Publication
Pharmacodynamic and Pharmacokinetic Profile of a Novel GLP-1...
Novel GLP-1 Receptor Biased Agonist
VIEW PublicationLatest Publication
USP7 Inhibitors Reveal a Differentiated Mechanism of p53-Driven...
Differentiated Mechanism of p53-Driven Anti-Cancer Activity
VIEW Publication